Dentatorubral-pallidoluysian atrophy or DRPLA (CAG)
Dentatorubral-pallidoluysian atrophy is a rare progressive brain
disorder caused by CAG expansion in the ATN1 gene which codes for a
polyglutamine tract in the alpha-1 protein. ATN1 is located on the short
arm of chromosome 12 and plays an important role in the development of
the brain and other organs as a nuclear transcriptional regulator. When
CAG repeats are more than 48, the protein becomes unstable and
accumulates in the neural cells.
Symptoms can start anywhere from 1 year of age to the age of 70, with the average symptom start at 30 years of age. The number of repeats in ATN1 correlate with symptom start, meaning that the higher they are the sooner and worse symptoms are. All individuals will show symptoms of progressive ataxia and cognitive decline. Seizures are a more common manifestation in the younger patient, especially under 20 years, and becomes a rarer manifestation as the individuals present older. Those over 20 years are more likely to experience choreoathetosis and psychiatric disturbances, that can range from delusions to psychosis. Brain MRI shows athrophy of the cerebellum and brain stem.
Disease duration can expand to 35 years, though on average it is only 8 years.
When a mutated ATN1 gene is inherited from a father, affected offsprings will normally experience symptoms 26-29 years earlier and 14-15 years earlier of the mutated gene is inherited from their mothers.
Main points
Symptoms can start anywhere from 1 year of age to the age of 70, with the average symptom start at 30 years of age. The number of repeats in ATN1 correlate with symptom start, meaning that the higher they are the sooner and worse symptoms are. All individuals will show symptoms of progressive ataxia and cognitive decline. Seizures are a more common manifestation in the younger patient, especially under 20 years, and becomes a rarer manifestation as the individuals present older. Those over 20 years are more likely to experience choreoathetosis and psychiatric disturbances, that can range from delusions to psychosis. Brain MRI shows athrophy of the cerebellum and brain stem.
Disease duration can expand to 35 years, though on average it is only 8 years.
When a mutated ATN1 gene is inherited from a father, affected offsprings will normally experience symptoms 26-29 years earlier and 14-15 years earlier of the mutated gene is inherited from their mothers.
Main points
- Autosomal dominant. Anticipation.
-
Gene: ATN1
- Normal: 6-35 repeats
- Premutated: 35-47 repeats. unstable, but rarely expands
- Mutated: > 48 repeats
- Protein: Atrophin-1
- Statistics: 5-7 per 1 million in Japan. Rarer in other places of the world.
-
Symptoms: Symptom start average at 30 years (range
1 to 70 years).
-
All ages present with ataxia and cognitive decline.
- < 20 years: Seizures
- > 20 years: choreoathetosis and psychiatric disturbances
- Treatment: Symptomatic.
- Diagnosis: Triple-primed PCR, Southern Blot.
Fragile X (CGG)
Fragile-X syndrome is a intellectual disability syndrome most often (98%
of cases) caused by a CGG repeat expansion in the 5' untranslated region
of a gene called Fragile X Messenger Ribonucleoprotein 1 (FMR1). The
FMR1 gene is located on the X-chromosome and is believed to be involved
in mRNA trafficking, moving mRNA from the nucleus to the cytoplasm. When
repeats are over 200, the gene is silenced which causes Fragile-X
syndrome. As the gene lies on chromosome X, all affected boys have
intellectual disability (moderate to severe) and some also autism
symptoms that can interfere with communication with others. As females
have two X-chromosomes, are not as severly affected, and are more likely
to be mildly affected. Theses individuals have long narrow faces with
broad forehead, prominent jaw and large ears. These facial features
become more apparent with age, and can be hard to notice in infancy.
These individuals are known to be hypotonic and suffer from joint
hypermobility. Males have machroorchidism, often not present until after
puberty.
Healthy carriers are those who are heterozygote for a premutation (50 to 300 repeats of CGG). Most of them will be asymptomatic, but some will develope one of the following syndromes, caused by increased levels of the FMR1 mRNA leading to intranuclear neuronal inclusions.
Fragile X-associated tremor/ataxia syndrome (FXTAS): can be seen in individuals with premutation, and is more commonly seen in male carriers. It is characterized by progressive cerebellar ataxia (can present as frequent falling) and tremor which is then followed by cognitive decline (can result in dementia). Symptoms most often start from the age of 60. (40% of male carriers. 16% of female carriers). On MRI white matter lesions can be seen in the middle cerebellar peduncles, splenium of corpus callosum or in cerebral white matter.
Fragile X-associated primary ovarian insufficiency (FXPOI): can be observed in women with a premutation. This most often presents as infertility or menopause in women younger than 40 years of age (ca. 20% of female carriers).
Fragile X-associated Neuropsychiatric Disorders (FXAND): affects about 50% of individuals with a premutation ({">"}50 repeats). Anxiety and depression is the most common presentation, but OCD, and ADHD is also seen.
Main points
Healthy carriers are those who are heterozygote for a premutation (50 to 300 repeats of CGG). Most of them will be asymptomatic, but some will develope one of the following syndromes, caused by increased levels of the FMR1 mRNA leading to intranuclear neuronal inclusions.
Fragile X-associated tremor/ataxia syndrome (FXTAS): can be seen in individuals with premutation, and is more commonly seen in male carriers. It is characterized by progressive cerebellar ataxia (can present as frequent falling) and tremor which is then followed by cognitive decline (can result in dementia). Symptoms most often start from the age of 60. (40% of male carriers. 16% of female carriers). On MRI white matter lesions can be seen in the middle cerebellar peduncles, splenium of corpus callosum or in cerebral white matter.
Fragile X-associated primary ovarian insufficiency (FXPOI): can be observed in women with a premutation. This most often presents as infertility or menopause in women younger than 40 years of age (ca. 20% of female carriers).
Fragile X-associated Neuropsychiatric Disorders (FXAND): affects about 50% of individuals with a premutation ({">"}50 repeats). Anxiety and depression is the most common presentation, but OCD, and ADHD is also seen.
Main points
- X-linked dominant
-
Gene: FMR1 (CGG repeats), 1% of affected
individuals has a partial or full deletion of the gene.
- Normal: 6-40 repeats
- Intermediate: 41-60 repeats. Offsprings NOT at increased risk
- Premutation: 61-200 repeats
- Full mutation: >200-230 repeats
- Protein: Fragile-X Messenger Ribonucleoprotein 1
-
Statistics:
- Premutation: 1/200 women carriers. 1/400 male carriers.
- Full mutation: 1/5000 women. 1/3600 males.
- Symptoms: Intellectual disability (moderate to severe, can be mild in females) and autistic features. Long and narrow face with a prominent jaw and broad forehead with large ears (face symptoms become more prominant with age). Macroorchidism (congenital or postpubertal). Joint laxity.
- Treatment: Symptomatic.
- Diagnosis: Triple-primed PCR, Southern Blot.
Friedreich Ataxia (GAA)
Friedreich Ataxia is a neurodegenerative disorder mainly caused by a GAA
repeat expansion in intron 1 in the gene FXN that is located on
chromosome 9. This gene codes for a mitochondrial protein which is
thought to be involved in iron-sulfur biogenesis and heme biosyntheses.
When the intron 1 repeats are over 66, the transcription of the gene is
reduced as the DNA becomes more condensed. This causes iron and ROS
overload in the mitochondria, and deficiency of ATP, which is essential
for producing cell energy. This reduction in energy will affect cells
that require high energy, like neural, muscle and pancreas cells. Most
individuals will show symptoms before the age of 25, most between 10-15
years, symptoms can, however, start later in life with some not showing
any symptoms until after 40 years of age.
Most cases start with progressive ataxia caused by loss of proprioception and spinocerebellar degeneration. This is followed by disarthria and distal muscle weakness. In majority of cases deep tendon reflexes are lost and babinski reflex is positive. Other symptoms include diabetes mellitus, kyphoscoliosis and hypertrophic cardiomyopathy which is the leading cause of death for these individuals.
As the disease is autosomal recessive, an individual needs to inherit two full mutated genes to show symptoms. These repeats can be of different length, and it seems that the shorter repeats correlates with symptom start and severity of symptoms. Mean life expectancy is about 40 years of age and it is vital that these individuals are diagnosed as soon as possible after symptom start, as correct treatment can increase their lifespan and reduce severity of symptoms.
Main points
Most cases start with progressive ataxia caused by loss of proprioception and spinocerebellar degeneration. This is followed by disarthria and distal muscle weakness. In majority of cases deep tendon reflexes are lost and babinski reflex is positive. Other symptoms include diabetes mellitus, kyphoscoliosis and hypertrophic cardiomyopathy which is the leading cause of death for these individuals.
As the disease is autosomal recessive, an individual needs to inherit two full mutated genes to show symptoms. These repeats can be of different length, and it seems that the shorter repeats correlates with symptom start and severity of symptoms. Mean life expectancy is about 40 years of age and it is vital that these individuals are diagnosed as soon as possible after symptom start, as correct treatment can increase their lifespan and reduce severity of symptoms.
Main points
- Autosomal recessive
-
Gene: FXN
- Normal: 5-33 repeats
- Premutation: 34-65
- Full mutation: >66 repeats
- Protein: Frataxin
-
Statistics:
- Premutation: 1/60 to 1/100
- Full mutation: 2-4/100.000 (Europe)
- Symptoms: Frequent falling and clumsiness caused by gait ataxia, loss of proprioception and muscle weakness. Dysarthria. Loss of deep tendon reflexes, and vibratory sense. Hypertrophic cardiomyopathy and diabetes mellitus. Kyphoscoliosis.
- Treatment: Symptomatic.
- Diagnosis: Triple-primed PCR, Southern Blot.
Huntington's disease
Huntington's disease start with a prodromal phase where cognitive
function is affected. This can appear as lack of emotional recognition,
and in executive thought process, which is vital in being able to
organize, plan and complete tasks ahead, as well as processing speed and
attention can be affected. Mood changes can also be observed in some,
like apathy and depression, some with suicidal thoughts. Some even
experience affective psychosis or schizophrenic psychosis. These
cognitive and personality changes are followed by subtle motor signs
like tics or twitches with incordination, restlessness and difficulty
with voluntary movement. The prodromal phase can start 15-20 years
before early symproms of clinical Hungtington's appear.
After the prodromal phase, symptoms of chorea start appearing with involuntary twitches in fingers, toes and face, and along with it cognitive function is increasingly affected as well. This makes it increasingly hard to complete task and participate in daily life. As the disease progresses, balance is affected, speaking and swallowing. Individuals become more apathetic, losing interest in activies they used to enjoy.
In the late-stage of Hungtington's rigidity and bradykinesia appear and in most cases symptoms of chorea disappears. At this stage, individuals are unable to care for themselves as walking, speaking and swallowing becomes increasingly harder.
The mean age of symptom onset is from 30-50 years of age, however, in 10% of cases symptoms start before the age of 20 (repeats often more than 55). In the juvenile form symptoms can present as progressive parkinsonism, ataxia, dementia with seizures.
Mean survival after the onset of symptoms is 15-18 years. The most common cause of death is aspiration pneumonia, and second suicide.
Main points
After the prodromal phase, symptoms of chorea start appearing with involuntary twitches in fingers, toes and face, and along with it cognitive function is increasingly affected as well. This makes it increasingly hard to complete task and participate in daily life. As the disease progresses, balance is affected, speaking and swallowing. Individuals become more apathetic, losing interest in activies they used to enjoy.
In the late-stage of Hungtington's rigidity and bradykinesia appear and in most cases symptoms of chorea disappears. At this stage, individuals are unable to care for themselves as walking, speaking and swallowing becomes increasingly harder.
The mean age of symptom onset is from 30-50 years of age, however, in 10% of cases symptoms start before the age of 20 (repeats often more than 55). In the juvenile form symptoms can present as progressive parkinsonism, ataxia, dementia with seizures.
Mean survival after the onset of symptoms is 15-18 years. The most common cause of death is aspiration pneumonia, and second suicide.
Main points
- Autosomal dominant
-
Gene: HHT
- Normal: < 26 repeats
- Intermediate: 27-35 repeats (unstable repeats, prone to expansion in the next generation, particularly if passed down by a male)
- Full mutated: > 35 repeats (Full penetrance of symptoms with repeats equal or over 40)
- Protein: Huntingtin
-
Statistics:
- Median survival: 15-18 years
- Mean age of symptom start: 40 years
- Symptoms: Progressive cognitive and motorfunction decline. First minor twitching occurs that later develops into chorea, that with time is replaced with rigidity and bradykinesia. This eventually makes individuals unable to take care of themselves as walking, swallowing and speaking becomes more difficult.
- Treatment: first and foremost supportive. Tetrabenazine and Deutetrabenazine is sometime used to treat symptoms of chorea.
- Diagnosis: Triple-primed PCR, Southern Blot.
Myotonic dystrophy type 1 (CTG)
Main points
- Autosomal dominant
-
Gene: DMPK
- Normal: 5-34 repeats
- Premutated(normal): 35-49 repeats
-
Mutated: >50 repeats
- Mild symptoms: 50-150 repeats (cataracts, mild myotonia with onset from 20-70 years)
- Classic symptoms: 100-1.000 repeats (cataracts, myotonia, frontal boldness, arrhythmia with onset from 10-30 years)
- Congenital form: >1.000 repeats (hypotonia, respiration affected, myotonia, cataracts, arrhythmia with onset from birth to 10 years)
- Protein: DM1 protein kinase
- Statistics: 1:20.000 (worldwide)
- Treatment:
- Diagnosis: Triple-primed PCR, Southern Blot.
Myotonic dystrophy type 2
Main points
- Gene:
- Protein:
- Statistics:
- Symptoms:
- Treatment:
- Diagnosis: Triple-primed PCR, Southern Blot.
Spinal and bulbar muscular atrophy
Main points
- Gene:
- Protein:
- Statistics:
- Symptoms:
- Treatment:
- Diagnosis: Triple-primed PCR, Southern Blot.
Spinocerebellar Ataxia
Main points
- Gene:
- Protein:
- Statistics:
- Symptoms:
- Treatment:
- Diagnosis: Triple-primed PCR, Southern Blot.